Compare HUT & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUT | COGT |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.5B |
| IPO Year | 2023 | 2018 |
| Metric | HUT | COGT |
|---|---|---|
| Price | $53.29 | $37.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 15 |
| Target Price | ★ $56.00 | $33.50 |
| AVG Volume (30 Days) | ★ 5.0M | 1.8M |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 672.73 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $162,385,000.00 | $7,871,000.00 |
| Revenue This Year | $74.79 | N/A |
| Revenue Next Year | $116.78 | $506.58 |
| P/E Ratio | $109.47 | ★ N/A |
| Revenue Growth | ★ 97.64 | N/A |
| 52 Week Low | $10.04 | $3.72 |
| 52 Week High | $66.07 | $43.73 |
| Indicator | HUT | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 52.47 |
| Support Level | $49.58 | $36.03 |
| Resistance Level | $55.20 | $39.82 |
| Average True Range (ATR) | 5.03 | 1.85 |
| MACD | -0.53 | 0.03 |
| Stochastic Oscillator | 48.34 | 55.09 |
Hut 8 Corp is an energy infrastructure operator and Bitcoin miner with self-mining, hosting, managed services, and traditional data center operations across North America. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.